Ayo S. Falade

Hematology | Oncology
5716 Cleveland St Ste 200
Virginia Beach, VA 23462

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 25 publications

Autologous Stem Cell Transplant Consolidation Is Associated With Improved Overall Survival in Angioimmunoblastic T-Cell Lymphoma: A Real-World National Cancer Database Study.

Autologous Stem Cell Transplant Consolidation Is Associated With Improved Overall Survival in Angioimmunoblastic T-Cell Lymphoma: A Real-World National Cancer Database Study.

Journal: Hematological oncology
Published: May 03, 2026

Outcomes of patients with relapsed or refractory classic Hodgkin lymphoma after frontline brentuximab vedotin.

Outcomes of patients with relapsed or refractory classic Hodgkin lymphoma after frontline brentuximab vedotin.

Journal: Blood cancer journal
Published: February 02, 2026

Nivolumab in combination with AVD as frontline treatment for patients with classic Hodgkin lymphoma: A real-world analysis from 20 US centers.

Nivolumab in combination with AVD as frontline treatment for patients with classic Hodgkin lymphoma: A real-world analysis from 20 US centers.

Journal: HemaSphere
Published: November 21, 2025

Treatment of Diffuse Large B-Cell Lymphoma.

Treatment of Diffuse Large B-Cell Lymphoma.

Journal: Mayo Clinic proceedings
Published: November 19, 2025

Impact of Novel Therapies on the Efficacy of Post-Transplantation Brentuximab Vedotin Maintenance in Hodgkin Lymphoma.

Impact of Novel Therapies on the Efficacy of Post-Transplantation Brentuximab Vedotin Maintenance in Hodgkin Lymphoma.

Journal: Blood advances
Published: October 10, 2025

Impact of novel therapies on the efficacy of posttransplantation brentuximab vedotin maintenance in Hodgkin lymphoma.

Impact of novel therapies on the efficacy of posttransplantation brentuximab vedotin maintenance in Hodgkin lymphoma.

Journal: Blood advances
Published: October 10, 2025

Real-world evidence for pembrolizumab gemcitabine vinorelbine and liposomal doxorubicin in classical Hodgkin lymphoma.

Real-world evidence for pembrolizumab gemcitabine vinorelbine and liposomal doxorubicin in classical Hodgkin lymphoma.

Journal: Blood advances
Published: September 02, 2025

Real-World Evidence for Pembrolizumab Gemcitabine Vinorelbine and Liposomal Doxorubicin in Classical Hodgkin Lymphoma.

Real-World Evidence for Pembrolizumab Gemcitabine Vinorelbine and Liposomal Doxorubicin in Classical Hodgkin Lymphoma.

Journal: Blood advances
Published: September 02, 2025

Acquired Gray platelet syndrome as a rare hematologic complication in a case of JAK2-positive post polycythemia Vera myelofibrosis.

Acquired Gray platelet syndrome as a rare hematologic complication in a case of JAK2-positive post polycythemia Vera myelofibrosis.

Journal: Annals of hematology
Published: June 25, 2025

PD-1-based combinations before autologous transplant are associated with improved outcomes in classical Hodgkin lymphoma.

PD-1-based combinations before autologous transplant are associated with improved outcomes in classical Hodgkin lymphoma.

Journal: Blood
Published: June 04, 2025

PD-1-based combinations before autologous transplant are associated with improved outcomes in classical Hodgkin lymphoma.

PD-1-based combinations before autologous transplant are associated with improved outcomes in classical Hodgkin lymphoma.

Journal: Blood
Published: June 04, 2025

Outcomes of patients with relapsed or refractory primary mediastinal B-cell lymphoma after frontline DA-EPOCH-R.

Outcomes of patients with relapsed or refractory primary mediastinal B-cell lymphoma after frontline DA-EPOCH-R.

Journal: Haematologica
Published: May 23, 2025
Showing 1-12 of 25

Last Updated: 09/26/2026